Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Galecto Inc (GLTO)

Galecto Inc (GLTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,460
  • Shares Outstanding, K 1,595
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,440 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 1.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -5.22
  • Growth Rate Est. (year over year) +19,237.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.70 +77.31%
on 12/02/25
38.33 -22.74%
on 12/26/25
+11.83 (+66.54%)
since 11/28/25
3-Month
3.50 +746.00%
on 10/02/25
38.33 -22.74%
on 12/26/25
+25.81 (+679.21%)
since 09/29/25
52-Week
2.01 +1,373.13%
on 04/09/25
38.33 -22.74%
on 12/26/25
+24.46 (+474.95%)
since 12/27/24

Most Recent Stories

More News
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified...

GLTO : 29.61 (-13.27%)
This Penny Stock Just Quadrupled. Should You Buy It Now?

Galecto stock skyrockets after announcing Damora Therapeutics acquisition. Here’s why GLTO shares are super unattractive to own at current levels.

GLTO : 29.61 (-13.27%)
Galecto Announces Acquisition of Damora Therapeutics

Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative...

GLTO : 29.61 (-13.27%)
Galecto Reports Third Quarter 2025 Operating and Financial Results

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced...

GLTO : 29.61 (-13.27%)
Galecto to Highlight GB3226 Program at ASH 2025

Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) ...

GLTO : 29.61 (-13.27%)
This Penny Stock Just Jumped 750%. Can It Retain These Gains for the Long Term?

Galecto stock soars as meme stock enthusiasts flock into the biotech name for no apparent reason. Here’s why GLTO shares are super risky to own at current levels.

GLTO : 29.61 (-13.27%)
Galecto Reports Second Quarter 2025 Operating and Financial Results

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced...

GLTO : 29.61 (-13.27%)
Galecto Reports First Quarter 2025 Operating and Financial Results

GLTO : 29.61 (-13.27%)
Galecto Reports Full-Year 2024 Financial Results

GLTO : 29.61 (-13.27%)
Galecto to Participate in Upcoming Investor Conferences

GLTO : 29.61 (-13.27%)

Business Summary

Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters...

See More

Key Turning Points

3rd Resistance Point 38.76
2nd Resistance Point 36.93
1st Resistance Point 33.27
Last Price 29.61
1st Support Level 27.78
2nd Support Level 25.95
3rd Support Level 22.29

See More

52-Week High 38.33
Last Price 29.61
Fibonacci 61.8% 24.45
Fibonacci 50% 20.17
Fibonacci 38.2% 15.88
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar